What is the Y-tunnus number of Leo Pharma Oy?

Leo Pharma Oy is registered with PRH / YTJ under Y-tunnus 0807589-1.

What is the revenue of Leo Pharma Oy?

Leo Pharma Oy reported revenue of EUR 10,9M in 2024.

Leo Pharma Oy employs 4 people as of the latest annual report.

Anja Cecilie Verhaug is the CEO of Leo Pharma Oy, in role since 2022.

Dilay Kücükkose chairs the board of Leo Pharma Oy, in role since 2025.

Leo Pharma Oy's registered address is Karhumäentie 3.

OYActive

Y-tunnus 0807589-1Karhumäentie 3, 01530 VantaaWholesale of pharmaceutical and medical goods· NACE 4646Est. 1990 · 35 years old4 employees

Actively employed in the business

Name	Role	Member since
Current (2)
JG Jakob Gregersen Deputy Member	Deputy Member	2024
AC Anja Cecilie Verhaug Chief Executive Officer	Chief Executive Officer	2022
Former (9)
EA Eetu Albert Aleksi Anttonen Audit	Audit	2013 – 2019
NM Nuno Miguel Pargana Brás Confidential Clerk	Confidential Clerk	2019 – 2020
NS Nicolai Salgaard Bendtsen Chief Executive Officer	Chief Executive Officer	2021 – 2021
CB Christian Bruun-Andersen Chief Executive Officer	Chief Executive Officer	2021 – 2022
JN Jesper Nørregaard Confidential Clerk	Confidential Clerk	2017 – 2019
KS Klaus Spärck Abel Chief Executive Officer	Chief Executive Officer	2019 – 2021
ST Sirpa Tuulikki Bergström Audit	Audit	2019 – 2023
MS Monica Shaw Deputy Member	Deputy Member	2021 – 2022
KD Kim Domela Kjøller Deputy Member	Deputy Member	2016 – 2021

Non-executive oversight

Name	Role	Member since
Current (1)
DK Dilay Kücükkose Chairperson	Chairperson	2025
Former (5)
GP Gitte Pugholm Aabo Chairperson	Chairperson	2016 – 2019
JH Jannie Holm Chairperson	Chairperson	2022 – 2024
AJ Anders John Krüger Chairperson	Chairperson	2024 – 2025
AK Anders Kronborg Board of Directors	Board of Directors	2016 – 2022
CT Catherine Thérése Jeanne Mazzacco Chairperson	Chairperson	2019 – 2022

As of last annual report

No shareholder data available.

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.